Elle, MD Biotechnologies
PrivateLast Round
Pre Seed
Jul 23, 2026
Total Funding Raised
$1.29M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Elle, MD Biotechnologies operates in Healthcare & Life Sciences and is based in Nova Scotia. Its latest recorded funding round was a Pre Seed round in July 2026.
Elle, MD Biotechnologies is a biotechnology company developing a novel, non-hormonal contraceptive device.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elle, MD Biotechnologies Comparables
Compare Elle, MD Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cirqle Biomedical | 81% | |
| 3Daughters | 77% | |
| Hervana Bio | 77% |
For institutional investors. Book with your work email.
Elle, MD Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Jul 23, 2026 | ||||
| Grant | Nov 28, 2025 | ||||
| Grant | Nov 3, 2025 | ||||
| Grant | Oct 21, 2025 | ||||
| Pre Seed | Oct 14, 2025 | ||||
SAFE | Jun 30, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Elle, MD Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovacorp | Pre Seed |
| H Venture Partners | Pre Seed |
| New Brunswick Innovation Foundation | Pre Seed |
| Atlantic Canada Opportunities Agency | Grant |
| National Research Council Canada | Grant |
| Community Business Development Corporation (CBDC) Hants-Kings | Pre Seed |
| Spring | Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 461% MoM, reaching 2.3K.
- Jul 23, 2026
$803K raised from H Venture Partners and Innovacorp.
For institutional investors. Book with your work email.
Elle, MD Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Elle, MD Biotechnologies's valuation, stock price, and market status.
Is Elle, MD Biotechnologies a public or private company?
Elle, MD Biotechnologies is a private company.
What is the current stock price of Elle, MD Biotechnologies?
Elle, MD Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Elle, MD Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Elle, MD Biotechnologies worth (valuation)?
Valuation information for Elle, MD Biotechnologies is not publicly available.
Can I buy Elle, MD Biotechnologies stock?
Elle, MD Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Elle, MD Biotechnologies's last funding round?
Elle, MD Biotechnologies's most recent funding round was Pre Seed on July 23, 2026.
Who are the main investors in Elle, MD Biotechnologies?
Key investors in Elle, MD Biotechnologies include Innovacorp, H Venture Partners, New Brunswick Innovation Foundation, Atlantic Canada Opportunities Agency, National Research Council Canada.
Will Elle, MD Biotechnologies IPO soon?
No public IPO plans have been announced for Elle, MD Biotechnologies.
How can I track Elle, MD Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Elle, MD Biotechnologies's shares on secondary markets.